← Back
Embecta
EMBC · listed on Nasdaq · worth $279.9 million
$6.19
−0.96% on Nov 2
Four insider buys in the last year, $557.9K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
54.8M shares
97% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Embecta stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Robert J. Hombach
Bought $223.8K on Aug 12 — 45,000 shares at $4.97, 41% of what they now own.
No earlier purchases to measure
President and CEO
Devdatt Kurdikar
Bought $140.9K on Aug 12 — 30,000 shares at $4.70, 3.7% of what they now own.
No earlier purchases to measure
Pres, Pharm Svc&Prod Mgmt, CLO
Jeffrey Z. Mann
Bought $99.8K on Aug 12 — 20,000 shares at $4.99, 7.6% of what they now own.
No earlier purchases to measure
Planned sales
Form 144 notices filed for Embecta in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Director Milton Mayo Morris filed to sell 6,293 shares on 4 Sep; no sale reported yetNotice on SEC.gov
All reports
Every insider trade and SEC report we hold for Embecta.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 13BoughtJeffrey Z. MannAug 13 · Traded Aug 12 · Pres, Pharm Svc&Prod Mgmt, CLO+7.6%20,000 @ $4.99$99.8K
Analysts, earnings and news
Analysts' price target
$4.00 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 5 quarters above
Q2 '26$0.56 a share+$0.30
Q1 '26$0.27 a share−$0.15
Q4 '25$0.71 a share+$0.04
Q3 '25$0.50 a share+$0.04